Analyst: Duodenoscope study is a ray of sunshine on a cloudy day for Ambu

After a discouraging financial guidance from Ambu, which doesn't provide any forecast for endoscope sales for the next financial year, the only saving grace Søren Løntoft Hansen sees for the medtech company is that it has presented exciting clinical data on a new single-use duodenoscope.
Photo: Sydbank/PR
Photo: Sydbank/PR
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

The big financial picture for Ambu this year had largely already been unveiled, and the focus was thus the medtech company's expectations for the upcoming 2021/2022 financial year when the company released a new report on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading